The Impact of COVID-19 On The Prostate Cancer Racial Disparity
COVID-19 delayed prostate cancer early detection screening and treatments. It also ushered in an increased use of telemedicine for prostate cancer care which is anticipated to expand and become more of a standard of care. This session will assess the impact of the pandemic, with a focus on how the increased use of telemedicine will impact the prostate cancer racial disparity based on the experiences and perspectives of doctors and patients.
AGENDA and PARTICIPANTS
All Sessions 1:00 PM to 3:30 PM ET
Welcome and Opening Remarks: Mr. Thomas Farrington, President and Founder, PHEN
Remarks: Congressman Gregory W. Meeks (D5-NY)
Moderator: Edith Mitchell, MD, MACP, FCPP, FRCP, Clinical Professor of Medicine and Medical Oncology; Department of Medical Oncology, Director, Center to Eliminate Cancer Disparities, Associate Director, Diversity Affairs, Sidney Kimmel Cancer Center at Jefferson
The COVID-19 Pandemic and Increased Telemedicine Use for Prostate Cancer: Daniela Wittman, PhD, MSW, Clinical Professor of Medicine, University of Michigan
Questions and Answers
PHEN Survey Results of Black Patients’ experiences and perspectives on Telemedicine: Keith Crawford, MD, PhD, Director of Clinical Trials and Patient Education, PHEN
-
-
- Pamela Coleman, MD, Associate Professor of Urology; Department of Surgery Howard University Hospital
- Robert Waterhouse Jr., MD, Urologist, Carolinas Medical Center
- J. Jacques Carter, MD, MPH, Professor of Medicine, Harvard Medical School
- Mr. Derrick Butts, Survivor / Author
- Mr. Azell Martin, Survivor
- Mr. Jimmy Barnes, Survivor
-
Closing Remarks
Be the first to comment